Trials / Completed
CompletedNCT03593187
A Study Evaluating the Safety of Cal-1 (LVsh5/C46) Drug Product in HIV-1 Infected Patient With High Risk Lymphoma
A Phase I/II Study of the Safety of CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, in HIV-1 Infected Patients With High-risk Lymphoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and the feasibility, and the success of engraftment of the introduction of Cal-1 gene-transduced haematopoietic cell populations (Ttn and HSPCtn) in patients with HIV-1-related high-risk lymphoma.
Detailed description
not provided
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cal-1 (LVsh5/C46) drug product | Autologous CD34+ Haematopoietic Stem/Progenitor Cells and CD4+ T Lymphocytes Transduced with LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct |
Timeline
- Start date
- 2019-01-15
- Primary completion
- 2020-07-28
- Completion
- 2020-07-28
- First posted
- 2018-07-20
- Last updated
- 2025-11-20
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03593187. Inclusion in this directory is not an endorsement.